Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system

European Journal of Medicinal Chemistry
2018.0

Abstract

The endocannabinoid system (ECS) represents one of the major neuromodulatory systems involved in different physiological and pathological processes. Multi-target compounds exert their activities by acting via multiple mechanisms of action and represent a promising pharmacological modulation of the ECS. In this work we report 4-substituted and 4,5-disubstituted 1,2-dihydro-2-oxo-pyridine-3-carboxamide derivatives with a broad spectrum of affinity and functional activity towards both cannabinoid receptors and additional effects on the main components of the ECS. In particular compound B3 showed high affinity for CB1R (Ki = 23.1 nM, partial agonist) and CB2R (Ki = 6.9 nM, inverse agonist) and also significant inhibitory activity (IC50 = 70 nM) on FAAH with moderate inhibition of ABHD12 (IC50 = 2.5 μΜ). Compounds B4, B5 and B6 that act as full agonists at CB1R and as partial agonists (B5 and B6) or antagonist (B4) at CB2R, exhibited an additional multi-target property by inhibiting anandamide uptake with sub-micromolar IC50 values (0.28-0.62 μΜ). The best derivatives showed cytotoxic activity on U937 lymphoblastoid cells. Finally, molecular docking analysis carried out on the three-dimensional structures of CB1R and CB2R and of FAAH allowed to rationalize the structure-activity relationships of this series of compounds.

Knowledge Graph

Similar Paper

Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system
European Journal of Medicinal Chemistry 2018.0
Biological evaluation of pyridone alkaloids on the endocannabinoid system
Bioorganic & Medicinal Chemistry 2017.0
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis
European Journal of Medicinal Chemistry 2020.0
New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis
Bioorganic & Medicinal Chemistry 2011.0
Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System
Journal of Medicinal Chemistry 2006.0
Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB<sub>2</sub>Cannabinoid Receptors Agonists:  Synthesis, Pharmacological Properties and Molecular Modeling
Journal of Medicinal Chemistry 2006.0
Structure–affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist
Bioorganic &amp; Medicinal Chemistry 2014.0
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry 2017.0
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists
Bioorganic &amp; Medicinal Chemistry Letters 2010.0
Identification of Endocannabinoid System-Modulating <i>N</i>-Alkylamides from <i>Heliopsis helianthoides</i> var. <i>scabra</i> and <i>Lepidium meyenii</i>
Journal of Natural Products 2014.0